Recombinant Virus Dengue Virus NS1 (Serotypes 1-4) His His (C-Term) Protein
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-14816
Key Product Details
Source
HEK293
Tag
His, His (C-Term)
Conjugate
Unconjugated
Product Specifications
Description
Recombinant Dengue Virus NS1 protein hexamer, pack of all 4 serotypes. Protein contains a C-terminal His-tag.
Purity
>95%
Activity
The resultant hexameric presentation is believed to be the biologically active form of NS1 involved in key aspects of dengue pathogenesis.
Protein / Peptide Type
Recombinant Protein
Formulation, Preparation and Storage
NBP3-14816
| Preparation Method | Recombinant Dengue Virus NS1 protein hexamer produced in HEK293 human cells. The resultant hexameric presentation is believed to be the biologically active form of NS1 involved in key aspects of dengue pathogenesis. Dengue Virus NS1 proteins are purified to a high degree, are in their native folding state, and possess all post-translational modifications. This advanced approach results in a product which delivers optimal antigenicity due to its human origin. |
| Formulation | DPBS pH 7.4 / Tris pH 8.5 |
| Preservative | No Preservative |
| Concentration | 0.5 mg/ml |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Store at 4C short term. Aliquot and store at -80C long term. Avoid freeze-thaw cycles. |
Background: Dengue Virus NS1
Dengue virus entry into host cells occurs via receptor-mediated endocytosis by receptor molecules including the mannose receptor, heparan sulfate, glycosaminoglycans, and DC-SIGN (1,3). Following attachment, the virus is endocytosed in clathrin-coated vesicles (1,3). Following internalization, clathrin disassembles and endosomal processing occurs, allowing viral fusion, disassembly, and release of viral RNA (1,3). This release results in viral translation and replication, virus assembly and maturation, and eventual exocytosis of the mature virus (1,3). Infection can result in a wide range of clinical symptoms including mild disease such as Dengue fever which is characterized by fever, headache, joint pain, rash, and retro-orbital pain, or severe, life-threatening conditions like Dengue hemorrhagic fever or Dengue shock syndrome which involves vascular permeability and leakage (1-3). Host immune response against infection includes innate immune response via interferon secretion and pro-inflammatory cytokine production, as well as adaptive immune response involving cellular and humoral components like T cell activation and B-cell mediated antibody production (1-3). As far as treatment for Dengue virus infection, there no commercial antiviral agents, though some anti-pyretics and certain phenolic compounds do show promise in treating infection (1-3). However, Resveratol, an antiviral for other Flavivirus, has been shown to directly attack the Dengue virus genome (1). While more work needs to be done, there are some live-attenuated tetravalent Dengue virus vaccine candidates in clinal trials including DENVax and TV003/TV005 (1-3).
References
1. Nanaware N, Banerjee A, Mullick Bagchi S, Bagchi P, Mukherjee A. Dengue Virus Infection: A Tale of Viral Exploitations and Host Responses. Viruses. 2021;13(10):1967. Published 2021 Sep 30. https://doi.org/10.3390/v13101967
2. Harapan H, Michie A, Sasmono RT, Imrie A. Dengue: A Minireview. Viruses. 2020;12(8):829. Published 2020 Jul 30. https://doi.org/10.3390/v12080829
3. Roy SK, Bhattacharjee S. Dengue virus: epidemiology, biology, and disease aetiology. Can J Microbiol. 2021;67(10):687-702. https://doi.org/10.1139/cjm-2020-0572
Long Name
Dengue Virus Nauru/West Pac/1974 Polyprotein
Alternate Names
Dengue NS1, Dengue NS1 protein, Dengue Virus
Additional Dengue Virus NS1 Products
Product Specific Notices
This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...